Suppliers / Zhejiang Tianyu Pharmaceutical

Zhejiang Tianyu Pharmaceutical

China 133 employees Updated 9 July 2026

Zhejiang Tianyu Pharmaceutical is an API manufacturer based in China. It holds 12 active US drug master files and 17 valid CEPs across a filed portfolio of 19 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 29 November 2024 as VAI.

12
active US DMFs
17
valid CEPs
3
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 29 November 2024 VAI US FDA
  • 4 March 2022 OAI US FDA
  • 12 April 2019 OAI US FDA
  • 12 June 2015 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Taizhou City, China Not on file
Taizhou, China Not on file
China, China 3010972581

What they file, and where

Molecule Regulators Docs
Losartan EDQM, SFDA (Saudi Arabia), US FDA 4
Valsartan EDQM, US FDA 4
Irbesartan EDQM, SFDA (Saudi Arabia) 3
Montelukast EDQM, US FDA 2
Olmesartan Medoxomil EDQM, SFDA (Saudi Arabia) 2
Rivaroxaban EDQM, US FDA 2
Sacubitril US FDA 2
Telmisartan EDQM 2
Brivaracetam EDQM 1
Cabozantinib US FDA 1
Show all 19 molecules on file
Candesartan Cilexetil EDQM 1
Dabigatran Etexilate Mesilate EDQM 1
Edoxaban US FDA 1
Ezetimibe US FDA 1
Losartan Potassium EDQM 1
Nicorandil EDQM 1
Olmesartan US FDA 1
Sitagliptin EDQM 1
Ticagrelor EDQM 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1
EMA None 1

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Tianyu Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 29 November 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates